Dianthus Therapeutics (DNTH) is a clinical-stage biotech company that develops antibody complement therapeutics. CEO Marino Garcia joins Oliver Renick to discuss DNTH. DNTH completed a merger with Magenta Therapeutics and began trading on the NASDAQ under the ticker “DNTH.” DNTH announced positive top-line phase 1 data for DNTH103 treatment. Tune in to find out more about the stock market today.
Morning Trade Live
15 Sep 2023
SHARE
The Watch List
02 Feb 2024
Morning Trade Live
29 Feb 2024
The Watch List
05 Mar 2024
Market On Close
01 Mar 2024
Market On Close
30 Jan 2024
Next Gen Investing
25 Apr 2024